{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=41",
    "query": {
      "intervention": "Continuous Dose",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 5323,
    "total_pages": 533,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T10:45:11.234Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05730920",
      "title": "IV Methadone Vs EXPAREL Erector Spinae Plane Blockade in Pediatric Subjects Undergoing Idiopathic Scoliosis Correction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Adolescent Idiopathic Scoliosis",
        "Juvenile Idiopathic Scoliosis"
      ],
      "interventions": [
        {
          "name": "Methadone",
          "type": "DRUG"
        },
        {
          "name": "Liposomal bupivacaine (LB, Exparel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Casey Stondell, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "11 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-10-19",
      "completion_date": "2024-09-21",
      "has_results": false,
      "last_update_posted_date": "2024-10-04",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05730920"
    },
    {
      "nct_id": "NCT05427123",
      "title": "Children's Bipolar Network Treatment Trial I",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bipolar Disorder",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Other Specified Bipolar and Related Disorder",
        "Mood Instability",
        "Child Mental Disorder",
        "Adolescent - Emotional Problem"
      ],
      "interventions": [
        {
          "name": "Medication or psychosocial treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "9 Years to 19 Years"
      },
      "enrollment_count": 80,
      "start_date": "2022-07-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05427123"
    },
    {
      "nct_id": "NCT04253262",
      "title": "A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2020-04-03",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Providence, Rhode Island",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04253262"
    },
    {
      "nct_id": "NCT00101010",
      "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "61 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "61 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2005-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 7,
      "location_summary": "Fort Smith, Arkansas • Grand Rapids, Michigan • Kalamazoo, Michigan + 4 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "East Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101010"
    },
    {
      "nct_id": "NCT07165327",
      "title": "Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gestatiaonl Diabetes Mellitus",
        "Pregnancy",
        "Diabetes in Pregnancy",
        "Insulin Dependent Diabetes Mellitus",
        "Insulin"
      ],
      "interventions": [
        {
          "name": "Injection Port for Insulin Administration",
          "type": "DEVICE"
        },
        {
          "name": "Single-Use Insulin Needles",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Texas at Austin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 44,
      "start_date": "2025-10",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07165327"
    },
    {
      "nct_id": "NCT01912560",
      "title": "Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemia",
        "Hypercholesterolemia",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "CAT-2003",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Statin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catabasis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 99,
      "start_date": "2013-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2016-07-28",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 13,
      "location_summary": "Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01912560"
    },
    {
      "nct_id": "NCT07005024",
      "title": "DOAC - Dosing Options in AntiCoagulation Prophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "VTE (Venous Thromboembolism)"
      ],
      "interventions": [
        {
          "name": "Apixaban 2.5 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Apixaban 5 mg once daily",
          "type": "DRUG"
        },
        {
          "name": "No anticoagulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 996,
      "start_date": "2025-10-17",
      "completion_date": "2035-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07005024"
    },
    {
      "nct_id": "NCT01843023",
      "title": "Extended Release Naltrexone for Opioid-Dependent Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Drug Dependence"
      ],
      "interventions": [
        {
          "name": "Extended Release Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Psychosocial Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Friends Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "15 Years to 21 Years"
      },
      "enrollment_count": 288,
      "start_date": "2013-06",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-10",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01843023"
    },
    {
      "nct_id": "NCT04676646",
      "title": "Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperkalaemia",
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Sodium zirconium cyclosilicate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 366,
      "start_date": "2021-03-08",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 12,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Hazel Crest",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676646"
    },
    {
      "nct_id": "NCT00388427",
      "title": "Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumour"
      ],
      "interventions": [
        {
          "name": "Dasatinib (BMS-354825)",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab (Erbitux, C225)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2007-06",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2015-05-28",
      "last_synced_at": "2026-11-06T10:45:11.234Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00388427"
    }
  ]
}